US2018186806A1PendingUtilityA1

Antiviral compounds

69
Assignee: GILEAD PHARMASSET LLCPriority: Nov 16, 2011Filed: Nov 30, 2017Published: Jul 5, 2018
Est. expiryNov 16, 2031(~5.3 yrs left)· nominal 20-yr term from priority
Inventors:Elizabeth M. BaconJeromy J. CottellAshley Anne KatanaDarryl KatoEvan S. KrygowskiJohn O. LinkJames G. TaylorChinh Viet TranTeresa Alejandra Trejo MartinZheng-Yu YangSheila Zipfel
A61P 31/12A61P 43/00A61P 31/14A61P 1/16A61K 31/4188A61K 31/7072A61K 38/21A61K 31/7064A61K 47/60C07D 491/052C07D 405/12A61K 38/06A61K 38/07A61K 31/7056A61K 45/06A61K 2300/00C07F 5/025Y10S514/894
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Claims

exact text as granted — not AI-modified
1 . A method of treating hepatitis C virus, said method comprising administering to a human patient in need thereof, a pharmaceutical composition which comprises a therapeutically effective amount of: (1) a compound of formula: 
       
         
           
           
               
               
           
         
       
       (2) a NSSB polymerase inhibitor; and (3) a NS3 protease inhibitor. 
     
     
         2 . The method of  claim 1 , wherein the NS3 protease inhibitor is boceprevir. 
     
     
         3 . The method of  claim 1 , wherein the NS3 protease inhibitor is telaprevir. 
     
     
         4 . The method of  claim 1 , wherein the NS3 protease inhibitor is TMC435350. 
     
     
         5 . The method of  claim 1 , wherein the NS3 protease inhibitor is BI-1335. 
     
     
         6 . The method of  claim 1 , wherein the NS3 protease inhibitor is BI-1230. 
     
     
         7 . The method of  claim 1 , wherein the NS3 protease inhibitor is MK-7009. 
     
     
         8 . The method of  claim 1 , wherein the NS3 protease inhibitor is VBY-376. 
     
     
         9 . The method of  claim 1 , wherein the NS3 protease inhibitor is ITMN-191. 
     
     
         10 . The method of  claim 1 , wherein the compound of formula: 
       
         
           
           
               
               
           
         
       
       and the NSSB polymerase inhibitor are administered together with the NS3 inhibitor. 
     
     
         11 . The method of  claim 1 , wherein the compound of formula: 
       
         
           
           
               
               
           
         
       
       and the NS5B polymerase inhibitor are administered separately from the NS3 inhibitor.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.